Characteristic | Training cohort | Validation cohort | P |
---|---|---|---|
Age, mean SD | 58.86 ± 12.38 | 59.12 ± 11.53 | 0.48 |
Tumor size, mean SD | 4.48 ± 1.91 | 4.53 ± 1.82 | 0.25 |
Sex (%) | 0.62 | ||
 Male | 258.0 (60.71%) | 167.0 (39.29%) |  |
 Female | 200.0 (58.65%) | 141.0 (41.35%) |  |
M stage (%) | 0.56 | ||
 M0 | 399.0 (60.27%) | 263.0 (39.73%) |  |
 M1 | 59.0 (56.73%) | 45.0 (43.27%) |  |
CA19-9 (%) | 0.94 | ||
 0–27 U/mL | 362.0 (59.64%) | 245.0 (40.36%) |  |
 ≥27 U/mL | 96.0 (60.38%) | 63.0 (39.62%) |  |
CEA (%) | 0.08 | ||
 0–5 ng/mL | 298.0 (62.34%) | 180.0 (37.66%) |  |
 ≥ 5 ng/mL | 160.0 (55.56%) | 128.0 (44.44%) |  |
Location (%) | 0.42 | ||
 Right | 208.0 (61.54%) | 130.0 (38.46%) |  |
 Left | 250.0 (58.41%) | 178.0 (41.59%) |  |
Grade (%) | 0.63 | ||
 High | 26.0 (5.68%) | 21.0 (6.82%) |  |
 Middle | 301.0 (65.72%) | 207.0 (67.21%) |  |
 Low | 131.0 (28.60%) | 80.0 (25.97%) |  |
Histotype (%) | 0.93 | ||
 Adenocarcinoma | 379.0 (82.75%) | 258.0 (83.77%) |  |
 Mucinous histology | 74.0 (16.16%) | 47.0 (15.26%) |  |
 Signet ring cell differentiation | 5.0 (1.09%) | 3.0 (0.97%) |  |